Aquestive Therapeutics, Inc. (AQST): Cost of Revenue
$18.55M
Year ended 2025-12-31
$17.83M
Trailing 12 months to 2026-06-30
-1.4%
3-year compound annual growth
+7.4%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.55M | +3.8% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $17.87M | -14.2% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $20.83M | +7.5% | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | $19.39M | n/a | 2024-03-05, From 2022-01-01 |
| No annual figure between 2020-12-31 and 2022-12-31. | |||
| 2020-12-31 | $12.96M | -36.3% | 2021-03-09, From 2020-01-01 |
| 2019-12-31 | $20.36M | n/a | 2021-03-09, From 2019-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $18.55M | +3.8% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $6.67M | +1.2% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $43.07M | -11.7% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $274.0K | -55.5% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $6.57M | +16.9% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $31.61M | +50.6% |
| Lftd Partners Inc. (LIFD) | 2025-12-31 | $24.30M | -1.1% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $6.34M | +52.3% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $24.05M | -0.6% |
Compare AQST, CPIX, INBP, LXRX side by side · Screen every company in Pharmaceutical Preparations ↗